Catalyst Pharmaceuticals, Inc. (CPRX) Files Form 4 Insider Buying : Patrick J Mcenany Buys 105,300 Shares

Catalyst Pharmaceuticals, Inc. (CPRX): Patrick J Mcenany , CEO of Catalyst Pharmaceuticals, Inc. purchased 105,300 shares on Jun 14, 2016. The Insider buying transaction was reported by the company on Jun 14, 2016 to the Securities and Exchange Commission. The shares were purchased at $0.65 per share for a total value of $68,529.24 , the company said in a SEC Form 4 Filing.

Other Insider transactions have been reported by the company according to SEC Form 4, on Apr 27, 2016, Charles B O’keeffe (director) purchased 20,000 shares at $0.60 per share price.On Apr 26, 2016, Patrick J Mcenany (CEO) purchased 50,000 shares at $0.65 per share price.Also, On Mar 17, 2016, Philip H Coelho (director) purchased 10,000 shares at $1.06 per share price.On Jan 12, 2016, Steve Miller (COO) purchased 7,933 shares at $1.80 per share price.

Shares of Catalyst Pharmaceuticals Inc (CPRX) ended Friday, Jun 10, 2016 session in red amid volatile trading. The shares closed down -0.033 points or -5.05% at $0.6201 with 3,09,896 shares getting traded. Post opening the session at $0.645, the shares hit an intraday low of $0.6112 and an intraday high of $0.645 and the price vacillated in this range throughout the day. The company has a market cap of $51 M and the number of outstanding shares has been calculated to be 8,28,70,649 shares. The 52-week high of Catalyst Pharmaceuticals Inc is $5.8 and the 52-week low is $0.51.

Catalyst Pharmaceuticals Inc Money Flow Index Chart

Company has been under the radar of several Street Analysts.Catalyst Pharmaceuticals Inc is Downgraded by Piper Jaffray to Neutral while Lowering the Price Target of the company shares to $ 1 from a previous price target of $6 . Earlier the firm had a rating of Overweight on the company shares. The Rating was issued on Apr 26, 2016.

Catalyst Pharmaceuticals Inc. formerly Catalyst Pharmaceutical Partners Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapies for people with rare debilitating diseases. The Company has three drugs in development: Firdapse CPP-109 and CPP-115. Firdapse is used for the treatments of lambert-eaton myasthenic syndrome (LEMS) and congenital myasthenic syndromes (CMS). CPP-115 is used for the treatment of addiction and epilepsy. CPP-109 is used to treat addiction. The Company is conducting a Phase III trial to determine the safety and efficacy of Firdapse in the treatment of LEMS. CPP-115 has been granted Orphan Drug Designation by the food and drug administration (FDA) for the treatment of infantile spasms and Orphan Medicinal Product Designation in the European Union for West syndrome (a form of infantile spasms).

Leave a Reply

Catalyst Pharmaceuticals Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on Catalyst Pharmaceuticals Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.